Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report

China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 20, 2022
  • PAGES：152
  • REPORT CODE：GMM1049072
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market. Detailed analysis of key players, along with key growth strategies adopted by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Qiagen NV

    • Leica Biosystems Nussloch GmBH

    • Foundation Medicine

    • Thermo Fisher Scientific Inc

    • F Hoffman La Roche

    • GE Healthcare

    • Agilent Technologies

    • Pfizer

    By Type:

    • PCR

    • In-situ Hybridization

    • Immunohistochemistry

    • Sequencing

    • Others

    By End-User:

    • Oncology

    • Neurological Disorders

    • Cardiovascular Disease

    • Immunological Disorders

    • Others

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of PCR from 2016 to 2027

    • 1.3.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of In-situ Hybridization from 2016 to 2027

    • 1.3.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Immunohistochemistry from 2016 to 2027

    • 1.3.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Sequencing from 2016 to 2027

    • 1.3.5 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Others from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Oncology from 2016 to 2027

    • 1.4.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Neurological Disorders from 2016 to 2027

    • 1.4.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Cardiovascular Disease from 2016 to 2027

    • 1.4.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Immunological Disorders from 2016 to 2027

    • 1.4.5 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Others from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Major Types

    • 3.4.1 Market Size and Growth Rate of PCR

    • 3.4.2 Market Size and Growth Rate of In-situ Hybridization

    • 3.4.3 Market Size and Growth Rate of Immunohistochemistry

    • 3.4.4 Market Size and Growth Rate of Sequencing

    • 3.4.5 Market Size and Growth Rate of Others

    4 Segmentation of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Oncology

    • 4.4.2 Market Size and Growth Rate of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Neurological Disorders

    • 4.4.3 Market Size and Growth Rate of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Cardiovascular Disease

    • 4.4.4 Market Size and Growth Rate of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Immunological Disorders

    • 4.4.5 Market Size and Growth Rate of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Others

    5 Market Analysis by Regions

    • 5.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production Analysis by Regions

    • 5.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 6.1 North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 6.2 North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    7 Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 7.1 Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 7.2 Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    8 South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 8.1 South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 8.2 South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    9 East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 9.1 East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 9.2 East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    10 Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 10.1 Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 10.2 Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    11 Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 11.1 Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 11.2 Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    12 Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis

    • 12.1 Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major Types

    • 12.2 Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Qiagen NV

      • 13.1.1 Qiagen NV Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Leica Biosystems Nussloch GmBH

      • 13.2.1 Leica Biosystems Nussloch GmBH Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Foundation Medicine

      • 13.3.1 Foundation Medicine Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 Thermo Fisher Scientific Inc

      • 13.4.1 Thermo Fisher Scientific Inc Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 F Hoffman La Roche

      • 13.5.1 F Hoffman La Roche Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 GE Healthcare

      • 13.6.1 GE Healthcare Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 Agilent Technologies

      • 13.7.1 Agilent Technologies Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 Pfizer

      • 13.8.1 Pfizer Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of PCR from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of In-situ Hybridization from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Immunohistochemistry from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Sequencing from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Oncology from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Neurological Disorders from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Cardiovascular Disease from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Immunological Disorders from 2016 to 2027

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Different Types from 2016 to 2027

    • Table Consumption Share of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of PCR

    • Figure Market Size and Growth Rate of In-situ Hybridization

    • Figure Market Size and Growth Rate of Immunohistochemistry

    • Figure Market Size and Growth Rate of Sequencing

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Different End-Users from 2016 to 2027

    • Table Consumption Share of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Oncology

    • Figure Market Size and Growth Rate of Neurological Disorders

    • Figure Market Size and Growth Rate of Cardiovascular Disease

    • Figure Market Size and Growth Rate of Immunological Disorders

    • Figure Market Size and Growth Rate of Others

    • Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production by Regions

    • Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production Share by Regions

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production Share by Regions in 2016

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production Share by Regions in 2021

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Production Share by Regions in 2027

    • Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Regions

    • Table China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Regions

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Regions in 2016

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Regions in 2021

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Regions in 2027

    • Table North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure North China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure Central China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure South China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure East China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure Northeast China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure Southwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Types from 2016 to 2027

    • Table Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2016

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2021

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by Types in 2027

    • Table Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by End-Users from 2016 to 2027

    • Table Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2016

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2021

    • Figure Northwest China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Qiagen NV

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Qiagen NV

    • Figure Sales and Growth Rate Analysis of Qiagen NV

    • Figure Revenue and Market Share Analysis of Qiagen NV

    • Table Product and Service Introduction of Qiagen NV

    • Table Company Profile and Development Status of Leica Biosystems Nussloch GmBH

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Leica Biosystems Nussloch GmBH

    • Figure Sales and Growth Rate Analysis of Leica Biosystems Nussloch GmBH

    • Figure Revenue and Market Share Analysis of Leica Biosystems Nussloch GmBH

    • Table Product and Service Introduction of Leica Biosystems Nussloch GmBH

    • Table Company Profile and Development Status of Foundation Medicine

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Foundation Medicine

    • Figure Sales and Growth Rate Analysis of Foundation Medicine

    • Figure Revenue and Market Share Analysis of Foundation Medicine

    • Table Product and Service Introduction of Foundation Medicine

    • Table Company Profile and Development Status of Thermo Fisher Scientific Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Thermo Fisher Scientific Inc

    • Figure Sales and Growth Rate Analysis of Thermo Fisher Scientific Inc

    • Figure Revenue and Market Share Analysis of Thermo Fisher Scientific Inc

    • Table Product and Service Introduction of Thermo Fisher Scientific Inc

    • Table Company Profile and Development Status of F Hoffman La Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffman La Roche

    • Figure Sales and Growth Rate Analysis of F Hoffman La Roche

    • Figure Revenue and Market Share Analysis of F Hoffman La Roche

    • Table Product and Service Introduction of F Hoffman La Roche

    • Table Company Profile and Development Status of GE Healthcare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GE Healthcare

    • Figure Sales and Growth Rate Analysis of GE Healthcare

    • Figure Revenue and Market Share Analysis of GE Healthcare

    • Table Product and Service Introduction of GE Healthcare

    • Table Company Profile and Development Status of Agilent Technologies

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Agilent Technologies

    • Figure Sales and Growth Rate Analysis of Agilent Technologies

    • Figure Revenue and Market Share Analysis of Agilent Technologies

    • Table Product and Service Introduction of Agilent Technologies

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US